RWA Wealth Partners LLC Sells 4,251 Shares of CVS Health Co. (NYSE:CVS)

RWA Wealth Partners LLC lessened its stake in CVS Health Co. (NYSE:CVS - Free Report) by 7.5% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 52,360 shares of the pharmacy operator's stock after selling 4,251 shares during the quarter. RWA Wealth Partners LLC's holdings in CVS Health were worth $2,350,000 at the end of the most recent reporting period.

Several other large investors also recently made changes to their positions in CVS. Ridgewood Investments LLC raised its position in CVS Health by 255.7% in the 4th quarter. Ridgewood Investments LLC now owns 626 shares of the pharmacy operator's stock valued at $28,000 after buying an additional 450 shares during the last quarter. Stonebridge Financial Group LLC bought a new position in shares of CVS Health during the 4th quarter worth approximately $28,000. Hopwood Financial Services Inc. acquired a new stake in shares of CVS Health in the fourth quarter valued at approximately $29,000. Legacy Investment Solutions LLC bought a new stake in shares of CVS Health in the third quarter worth $31,000. Finally, Financial Perspectives Inc boosted its holdings in CVS Health by 137.5% during the fourth quarter. Financial Perspectives Inc now owns 805 shares of the pharmacy operator's stock worth $36,000 after purchasing an additional 466 shares during the last quarter. Institutional investors own 80.66% of the company's stock.

Insiders Place Their Bets

In other CVS Health news, SVP James David Clark sold 7,513 shares of the firm's stock in a transaction on Wednesday, March 5th. The stock was sold at an average price of $66.35, for a total value of $498,487.55. Following the sale, the senior vice president now owns 8,394 shares of the company's stock, valued at approximately $556,941.90. This trade represents a 47.23 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Michael F. Mahoney purchased 30,000 shares of the stock in a transaction dated Tuesday, February 18th. The shares were acquired at an average cost of $66.70 per share, with a total value of $2,001,000.00. Following the acquisition, the director now directly owns 39,356 shares in the company, valued at $2,625,045.20. This represents a 320.65 % increase in their position. The disclosure for this purchase can be found here. Corporate insiders own 0.24% of the company's stock.

Remove Ads

CVS Health Stock Performance

Shares of CVS traded down $3.97 during mid-day trading on Friday, hitting $63.54. 13,291,234 shares of the company's stock were exchanged, compared to its average volume of 11,566,187. The company has a quick ratio of 0.60, a current ratio of 0.81 and a debt-to-equity ratio of 0.80. CVS Health Co. has a 52 week low of $43.56 and a 52 week high of $75.12. The stock's 50-day simple moving average is $63.47 and its 200-day simple moving average is $58.01. The firm has a market cap of $80.11 billion, a price-to-earnings ratio of 17.36, a price-to-earnings-growth ratio of 0.98 and a beta of 0.54.

CVS Health (NYSE:CVS - Get Free Report) last posted its quarterly earnings data on Wednesday, February 12th. The pharmacy operator reported $1.19 EPS for the quarter, topping analysts' consensus estimates of $0.89 by $0.30. CVS Health had a return on equity of 9.11% and a net margin of 1.24%. On average, equities research analysts expect that CVS Health Co. will post 5.89 EPS for the current year.

CVS Health Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, May 1st. Investors of record on Tuesday, April 22nd will be given a dividend of $0.665 per share. The ex-dividend date is Tuesday, April 22nd. This represents a $2.66 annualized dividend and a yield of 4.19%. CVS Health's dividend payout ratio is 72.68%.

Wall Street Analyst Weigh In

CVS has been the subject of several analyst reports. Barclays raised their price objective on CVS Health from $71.00 to $73.00 and gave the company an "overweight" rating in a report on Thursday, February 13th. Wells Fargo & Company increased their price objective on CVS Health from $68.00 to $73.00 and gave the company an "overweight" rating in a report on Thursday, February 13th. Cantor Fitzgerald upgraded shares of CVS Health from a "neutral" rating to an "overweight" rating in a research note on Wednesday, February 12th. Leerink Partners upgraded CVS Health from a "market perform" rating to an "outperform" rating and lifted their price target for the stock from $55.00 to $75.00 in a report on Thursday, February 13th. Finally, Truist Financial upped their price objective on CVS Health from $60.00 to $76.00 and gave the company a "buy" rating in a research note on Thursday, February 13th. Four analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $70.39.

CVS Health Company Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.